Market Cap 283.45M
Revenue (ttm) 22.27M
Net Income (ttm) -40.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -181.72%
Debt to Equity Ratio 0.00
Volume 1,116,300
Avg Vol 1,263,490
Day's Range N/A - N/A
Shares Out 45.72M
Stochastic %K 22%
Beta 0.68
Analysts Strong Sell
Price Target $20.60

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 727 1755
Address:
10865 Road to the Cure, Suite 150, San Diego, United States
scaredmoneymakenomoney
scaredmoneymakenomoney Oct. 26 at 9:39 PM
$CAPR gonna slap that ask first thing when markets open
1 · Reply
Cote0924
Cote0924 Oct. 26 at 8:21 PM
$CAPR After almost 6 years invested in capricor this may be my last SP guess….. $12-$14 run up into data release When LEVF and PUL both meet endpoints….PM price is $25 and hits $40 intra day Long and strong my friends. Godspeed to the boys who need deramiocel 🫡🫡
1 · Reply
dnfrs
dnfrs Oct. 26 at 8:01 PM
$CAPR If Novartis paid $12 Billion to buyout Avidity...what is Capricor worth? Deramiocel has a much more important impact on ALL DMD boys...and the StealthX platform has application to literally hundreds of vaccine, cancer and immunotherapy applications.
2 · Reply
PhantomZ
PhantomZ Oct. 26 at 6:33 PM
$CAPR https://investors.aviditybiosciences.com/2025-10-26-Avidity-Biosciences-Enters-into-Agreement-to-be-Acquired-by-Novartis-AG
1 · Reply
Ag035
Ag035 Oct. 26 at 5:40 PM
$CAPR Crazy times, their current MC is 6.7 billion. https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-acquire-avidity-biosciences-12-billion-2025-10-26/
1 · Reply
The_Fact_ster
The_Fact_ster Oct. 26 at 5:25 PM
$CAPR LMAO still living rent free in WBinthehouse's head
1 · Reply
dnfrs
dnfrs Oct. 26 at 5:17 PM
$CAPR The recent corporate presentation on slide 37 reads... "Active NIH Collaboration Underway Exosome-Based Multivalent Vaccine  Capricor’s StealthX vaccine was selected by Project NextGen • Aim is to advance a pipeline of innovative vaccines which may provide broader and more durable protection against COVID-19 and other potential infectious threats  The National Institute of Allergy and Infectious Diseases (NIAID) is conducting and funding the Phase 1 clinical trial • Study is underway with topline data expected in ~Q1 2026 • Capricor is supplying investigational product  If NIAID finds our vaccine meets its criteria for safety and efficacy, they may consider our program for a funded Phase 2 ClinicalTrials.gov ID: NCT07095231 " This all good news and I have to wonder if the potentially fully funded phase 2 might be large enough to be pivotal? If the Feds urgently want to get something better and safer than mRNA vaccines StealthX vaccines can answer their needs !
0 · Reply
snowboy
snowboy Oct. 26 at 4:31 PM
$CAPR Busy couple of weeks upcoming for Linda and team. Please remember that the gene nerds at $SRPT and others will be needed for true cures. Once concept of exosome-based treatment proved, work will start on using StealthX platform to float gene therapies to muscles so that the damned AAV vectors and their incipient side effects can be ditched. ​For instance, $QURE will be able to float Huntingdon gene fix to brain using IV administered exosome carrier, eliminating manual placement in brain via surgery. I am remaining incredibly long investor from here... $40 billion MC or buyout. 30 minutes to kickoff. See ya at Thanksgiving.
0 · Reply
lymond
lymond Oct. 26 at 3:41 PM
$CAPR Looks like we'll be getting a video from MRC soon, "sharing our belief that the treatment is working." https://musculardystrophynews.com/columns/im-giving-everything-have-duchenne-md-own-way
3 · Reply
WBinthehouse
WBinthehouse Oct. 26 at 3:36 PM
$CAPR I see Fud posting BP should buy NS, but NS only has rights to Deramiocel for DMD only. So not really getting all of CAPR if anyone buys NS. Just proves some are not totally in the know.
1 · Reply
Latest News on CAPR
Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026

Sep 29, 2025, 3:51 PM EDT - 27 days ago

Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026


Capricor Therapeutics, Inc. - Special Call

Sep 25, 2025, 11:07 AM EDT - 4 weeks ago

Capricor Therapeutics, Inc. - Special Call


Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

Jul 11, 2025, 9:03 AM EDT - 3 months ago

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock


US FDA declines to approve Capricor's muscle disorder therapy

Jul 11, 2025, 6:36 AM EDT - 3 months ago

US FDA declines to approve Capricor's muscle disorder therapy


Why Is Capricor Therapeutics Stock Trading Lower On Monday?

Jun 23, 2025, 12:46 PM EDT - 4 months ago

Why Is Capricor Therapeutics Stock Trading Lower On Monday?


scaredmoneymakenomoney
scaredmoneymakenomoney Oct. 26 at 9:39 PM
$CAPR gonna slap that ask first thing when markets open
1 · Reply
Cote0924
Cote0924 Oct. 26 at 8:21 PM
$CAPR After almost 6 years invested in capricor this may be my last SP guess….. $12-$14 run up into data release When LEVF and PUL both meet endpoints….PM price is $25 and hits $40 intra day Long and strong my friends. Godspeed to the boys who need deramiocel 🫡🫡
1 · Reply
dnfrs
dnfrs Oct. 26 at 8:01 PM
$CAPR If Novartis paid $12 Billion to buyout Avidity...what is Capricor worth? Deramiocel has a much more important impact on ALL DMD boys...and the StealthX platform has application to literally hundreds of vaccine, cancer and immunotherapy applications.
2 · Reply
PhantomZ
PhantomZ Oct. 26 at 6:33 PM
$CAPR https://investors.aviditybiosciences.com/2025-10-26-Avidity-Biosciences-Enters-into-Agreement-to-be-Acquired-by-Novartis-AG
1 · Reply
Ag035
Ag035 Oct. 26 at 5:40 PM
$CAPR Crazy times, their current MC is 6.7 billion. https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-acquire-avidity-biosciences-12-billion-2025-10-26/
1 · Reply
The_Fact_ster
The_Fact_ster Oct. 26 at 5:25 PM
$CAPR LMAO still living rent free in WBinthehouse's head
1 · Reply
dnfrs
dnfrs Oct. 26 at 5:17 PM
$CAPR The recent corporate presentation on slide 37 reads... "Active NIH Collaboration Underway Exosome-Based Multivalent Vaccine  Capricor’s StealthX vaccine was selected by Project NextGen • Aim is to advance a pipeline of innovative vaccines which may provide broader and more durable protection against COVID-19 and other potential infectious threats  The National Institute of Allergy and Infectious Diseases (NIAID) is conducting and funding the Phase 1 clinical trial • Study is underway with topline data expected in ~Q1 2026 • Capricor is supplying investigational product  If NIAID finds our vaccine meets its criteria for safety and efficacy, they may consider our program for a funded Phase 2 ClinicalTrials.gov ID: NCT07095231 " This all good news and I have to wonder if the potentially fully funded phase 2 might be large enough to be pivotal? If the Feds urgently want to get something better and safer than mRNA vaccines StealthX vaccines can answer their needs !
0 · Reply
snowboy
snowboy Oct. 26 at 4:31 PM
$CAPR Busy couple of weeks upcoming for Linda and team. Please remember that the gene nerds at $SRPT and others will be needed for true cures. Once concept of exosome-based treatment proved, work will start on using StealthX platform to float gene therapies to muscles so that the damned AAV vectors and their incipient side effects can be ditched. ​For instance, $QURE will be able to float Huntingdon gene fix to brain using IV administered exosome carrier, eliminating manual placement in brain via surgery. I am remaining incredibly long investor from here... $40 billion MC or buyout. 30 minutes to kickoff. See ya at Thanksgiving.
0 · Reply
lymond
lymond Oct. 26 at 3:41 PM
$CAPR Looks like we'll be getting a video from MRC soon, "sharing our belief that the treatment is working." https://musculardystrophynews.com/columns/im-giving-everything-have-duchenne-md-own-way
3 · Reply
WBinthehouse
WBinthehouse Oct. 26 at 3:36 PM
$CAPR I see Fud posting BP should buy NS, but NS only has rights to Deramiocel for DMD only. So not really getting all of CAPR if anyone buys NS. Just proves some are not totally in the know.
1 · Reply
dnfrs
dnfrs Oct. 26 at 3:33 PM
$CAPR In a few weeks we should have both the phase 3 deramiocel topline LVEF and PUL data. I expect both to be successful. I am also hopeful that we will get a Quarterly Report update on the NIAID funded StealthX exosome Covid vaccine trial and at least an overview of the progress on the entire StealthX platform ! A lot of good news coming IMO !
0 · Reply
neelsen01
neelsen01 Oct. 26 at 1:06 PM
$CAPR Cash floor seen at around $3/share…
1 · Reply
neelsen01
neelsen01 Oct. 26 at 1:05 PM
$CAPR Looking to sell the Nov 21 $2.50 puts for $0.25 if IV increases…
1 · Reply
jamestrade07
jamestrade07 Oct. 26 at 12:34 PM
$CAPR within less than a week from the time they unblind the data they should have a pretty good idea if the trail was successful or not. The fact they have added /or republished 4 new jobs this week is encouraging and if they will add more jobs in the coming days we can almost certainly assume they are happy with the results. I'm banking on LEVF hitting stat sig and PUL narrowly hitting or missing. If LEVF hits then the FDA will most certainly approve the drug and if PUL norrowly misses they can reach an agreement with the FDA to keep hope 3 OLE running for another year and than submitting the PUL 2 data next year. If this data will be stat sig they will be able to update the label.
1 · Reply
Stormfury66
Stormfury66 Oct. 26 at 12:26 PM
$CAPR PART 2 LVEF End point hits 70-80% PUL2.0 60-70% = FDA Approval 300%+ squeeze LONG TERM INVESTORS HOLD & trust Linda & team NEWBIES do ur own DD & if you decide to get on board with us “ good move “ It’s been an extremely agonizing ride over the years & I know some doubt has crept in .. but this is it .. ALL on the line for EVERYONE but just think about what it will mean to the children as it signifies HOPE .. as in HOPE-3 to cross the finish line . One of the most undervalued stock in the bio industry
0 · Reply
mmc100
mmc100 Oct. 26 at 12:25 PM
0 · Reply
Stormfury66
Stormfury66 Oct. 26 at 12:16 PM
$CAPR Im with @LineBacker04 .. LVEF has a very good probability of hitting its endpoints . Even if PUL misses ( odds favor it won’t ) but if it does miss & LVEF hits for the heart FDA approval will take place , just the labeling will not be as expansive . Earnings date is Nov 12th , this could be moved around some pending data release . Regardless the 2nd week of Nov & on CAPR will experince extreme volatility as Bulls vs Bear cases will run rampant . My stance as a HEAVY investor & following CAPR for many years & from everything I’ve had heard from Linda & FDA stating they are aligned with CAPR & have FLEXIBILITY in determining the approval & allowing resubmission with Hope-3 data , I strongly believe we will cross the long awaited finish line , Linda came on board in 2005 with her expertise in cardiac working to slow down heart deterioration , thus allowing those suffering from DMD a stronger & living a longer duration & actually enjoying life . All this will mean a breakthrough
1 · Reply
Stormfury66
Stormfury66 Oct. 26 at 11:37 AM
$CAPR Exact date is hard to say , however data release is due Mid this quarter that would place it ard NOV 15th ..
0 · Reply
great_investment_thesis
great_investment_thesis Oct. 26 at 11:10 AM
$CAPR I'm new here, so I'll be brief, as I respect the knowledge of the long-time holders. I just invested a significant amount. My thesis is simple: LVEF data is 100% hitting. That translates to 3X. Don't care about PUL 2.0 (total bonus). The LVEF P-value from HOPE-2 is all that matters, and that's rock solid.
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 26 at 8:31 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CAPR Current Share Price: $6.20 Contracts: $CAPR January 15, 2027 $8 Calls Scale in: $2.93- $3.58 Scale out: $4.55-$5.85 Can Easily Capture: 60% ROI Blended DTE: 446 Days | Join Elites here: https://liquidtheta.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 26 at 6:38 AM
Enter: $CAPR Calls Strike Price: $8 Expiry Date: NOV 21 2025 Buy in Price: $1.70 - $2.10 Sell Price: $3.86 Profit : +127% (Turn every $1 into $2.27) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
Its_Never_Too_Late
Its_Never_Too_Late Oct. 26 at 4:20 AM
$CAPR We are one day closer to potentially seeing deramiocel being shut down as a program. Once we see the results of HOPE-3 we will know. Im betting with my many decades of biotechnology inveating experience that HOPE-3 MISSES ALL endpoints. $CAPR
1 · Reply